Tiziana files patent on combination of NP-ACT D with anti-IL-6R
Category: #health  By Saipriya Iyer  Date: 2020-04-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

Tiziana files patent on combination of NP-ACT D with anti-IL-6R

Tiziana Life Sciences, a biotechnology company, has recently announced the filing of a provisional patent application on a potential therapy for the COVID-19 disease. This potential therapy is the combination of NP-ACT D (nanoparticle-Actinomycin D) with anti-IL-6R (anti-interleukin-6 receptor monoclonal antibody).

The underlying concepts of the invention are based on the hypothesis that the combination of an anti-inflammatory agent, such as anti-IL-6R, that suppresses ‘Cytokine Storm’ with an antiviral drug that controls the proliferation of coronavirus may deliver immediate relief to severely infected COVID-19 patients.

ACT D (Actinomycin D), an antibiotic drug, is on the WHO’s List of Essential Medicines. However, severe complications and toxicities associated with the IV administration of this antibiotic drug limits its therapeutic utility. These severe toxicities may be overcome by NP-ACT D formulation. For instance, an animal study that compared NP-ACT D side-by-side with an equivalent dose of free ACT D resulted in 0% mortality among rats that were dosed with the NP-ACT D, where free ACT D dosed rats showed > 90% mortality. Nevertheless, the tolerability and safety of NP-ACT D are yet to be examined among healthy volunteers before advancing to the clinical studies.

Coronavirus-infected patients are known to develop cytokine storm, which is an uncontrolled immune response. It results in an excessive production of IL-6, TNF-a, and other inflammatory cytokines that potentially cause chronic inflammation. These cytokines are also believed to be linked with ARDS (acute respiratory distress syndrome) and severe lung damage in COVID-19 patients. Therefore, the company considers the potential combination of TZLS-501 and NP-ACT D to hinder viral proliferation and control lungs inflammation to reduce mediated lung damage & death of COVID-19 patients.

Tiziana has not conducted any pre-clinical or clinical research of NP-ACT D, either alone or by combining with anti-IL-6R to treat COVID-19 disease. However, it has established theoretical principals for drug combinations and is forming an assessment for the potential of the combination of research & anecdotal evidence that involves the activity of NP-ACT D on other coronavirus strands.

Source credit:

https://www.globenewswire.com/news-release/2020/04/27/2022531/0/en/Tiziana-Life-Sciences-Files-Patent-on-Combination-of-Nanoparticle-Actinomycin-D-with-Anti-Interleukin-6-Receptor-Monoclonal-Antibody-for-Treatment-of-Coronaviruses.html



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

AdaptHealth enters definitive deals to acquire Solara & ActivStyle
AdaptHealth enters definitive deals to acquire Solara & ActivStyle
By Saipriya Iyer

AdaptHealth Corp. has recently entered two separate definitive agreements for the acquisition of Solara Medical Supplies, LLC and ActivStyle, Inc. AdaptHealth is a leading home medical supplies, equipment, and other re...

Ambani’s JioMart unveils a new website to deliver orders across India
Ambani’s JioMart unveils a new website to deliver orders across India
By Saipriya Iyer

Jio Platforms, the top telecom operator along with Jio Retail, which is the top retail chain has recently unveiled JioMart’s new website and has begun taking orders in a large amount from tier 1, tier 2 and metro c...

Omada enters $30M acquisition deal with digital health company Physera
Omada enters $30M acquisition deal with digital health company Physera
By Saipriya Iyer

Omada Health, which has raised nearly $57 million in funding, has reportedly acquired a digital health company, Physera. It provides remote physical therapy to its customers.

The co...